Company_NN Information_NN 143_CD 5_CD RESERVES_NNP Share_NNP Capital_NNP Profit_NNP 2004_CD premium_NN redemption_NN Other_JJ and_CC loss_NN 2005_CD Total_JJ account_NN reserve_NN reserves_NNS account_VBP Total_JJ restated_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD As_IN previously_RB reported_VBN 550_CD 36_CD 1,841_CD 23,540_CD 25,967_CD 28,448_CD On_IN adoption_NN of_IN FRS_NNP 21_CD 1,061_CD 1,061_CD 914_CD At_IN beginning_NN of_IN year_NN revised_VBN 550_CD 36_CD 1,841_CD 24,601_CD 27,028_CD 29,362_CD Net_JJ gains_NNS for_IN the_DT year_NN 1,268_CD 1,268_CD 1,172_CD Dividends_NNS 1,676_CD 1,676_CD 1,408_CD Share_NN re-purchases_VBZ 17_CD 3,001_CD 2,984_CD 2,199_CD Share_NN premiums_NNS 142 142 101_CD At_IN end_NN of_IN year_NN 692_CD 53_CD 1,841_CD 21,192_CD 23,778_CD 27,028_CD Distributable_JJ reserves_NNS at_IN end_NN of_IN year_NN 733_CD 4,325_CD 5,058_CD 2,269_CD As_IN permitted_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Company_NN has_VBZ not_RB presented_VBN its_PRP$ profit_NN and_CC loss_NN account_NN ._.
At_IN 31_CD December_NNP 2005_CD $_$ 16,867_CD m_NN 31_CD December_NNP 2004_CD $_$ 22,923_CD m_NN of_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN was_VBD not_RB available_JJ for_IN distribution_NN ._.
The_DT majority_NN of_IN this_DT non-distributable_JJ amount_NN relates_VBZ to_TO profit_VB arising_VBG on_IN the_DT sale_NN of_IN Astra_NNP AB_NNP to_TO a_DT subsidiary_NN in_IN 1999_CD ,_, which_WDT becomes_VBZ distributable_JJ as_IN the_DT underlying_VBG receivable_NN is_VBZ settled_VBN ._.
During_IN 2005_CD ,_, $_$ 6,056_CD m_NN of_IN the_DT profit_NN was_VBD realized_VBN by_IN repayment_NN ._.
Subsequent_JJ to_TO the_DT year_NN end_NN ,_, a_DT further_JJ $_$ 587m_CD was_VBD repaid_VBN on_IN 26_CD January_NNP 2006_CD ,_, resulting_VBG in_IN additional_JJ distributable_JJ reserves_NNS not_RB included_VBD in_IN the_DT figures_NNS above_IN ._.
Included_VBN in_IN other_JJ reserves_NNS is_VBZ a_DT special_JJ reserve_NN of_IN $_$ 157m_CD ,_, arising_VBG on_IN the_DT redenomination_NN of_IN share_NN capital_NN in_IN 1999_CD ._.
6_CD RECONCILIATION_NNP OF_IN MOVEMENT_NNP IN_IN SHAREHOLDERS_NNP FUNDS_NNP 2004_CD 2005_CD restated_VBN $_$ m_CD $_$ m_CD Shareholders_NNS funds_NNS at_IN beginning_NN of_IN year_NN 27,439_CD 29,785_CD Net_JJ gains_NNS for_IN the_DT financial_JJ year_NN 1,268_CD 1,172_CD Dividends_NNS 1,676_CD 1,408_CD Issues_NNS of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 143_CD 102_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 3,001_CD 2,212_CD Net_JJ reduction_NN in_IN shareholders_NNS funds_NNS 3,266_CD 2,346_CD Shareholders_NNS funds_NNS at_IN end_NN of_IN year_NN 24,173_CD 27,439_CD
